Klaus Mendla acts as an external business development consultant to Angelini Ventures. He is a life sciences professional with strong scientific background and proven track record in Pharma business development in the field of Central Nervous System (CNS) diseases.

Prior to joining Angelini, Klaus was Global Head of Business Development & Licensing CNS at Boehringer Ingelheim (BI), with worldwide responsibility for all Pharma partnering activities in the company’s therapeutic area CNS diseases. In this role, Klaus took the lead on developing and implementing BI’s strategy for partnering in the neurology and neuropsychiatry space. He and his team successfully concluded numerous research collaboration and licensing agreements with Pharma and Biotech companies, with a total deal value in the multi-billion-Euro range.

Before joining BI’s global business development and licensing organization, Klaus was director of Molecular Biology and Neurodegenerative Diseases Research at BI, where he led drug discovery teams focused on novel treatments for Alzheimer’s disease and other neurodegenerative disorders.

Klaus received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship at the University of Heidelberg on the pathophysiology of lysosomal storage diseases.